How to cite this article: Callewaert M, Dukic S, Van Gulick L, Vittier M, Gafa V, Andry M-C, Molinari M, Roullin VG. 2013. Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency. J Biomed Mater Res Part A 2013:101A:1319–1327.
Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency†
Article first published online: 15 OCT 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Biomedical Materials Research Part A
Volume 101A, Issue 5, pages 1319–1327, May 2013
How to Cite
Callewaert, M., Dukic, S., Van Gulick, L., Vittier, M., Gafa, V., Andry, M.-C., Molinari, M. and Roullin, V. G. (2013), Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency. J. Biomed. Mater. Res., 101A: 1319–1327. doi: 10.1002/jbm.a.34442
- Issue published online: 25 MAR 2013
- Article first published online: 15 OCT 2012
- Manuscript Accepted: 20 AUG 2012
- Manuscript Revised: 20 JUL 2012
- Manuscript Received: 16 MAY 2012
- La Ligue Contre le Cancer (section Marne). Grant Number: 2007.10.0640
- The Region Champagne Ardenne, the DRRT Champagne Ardenne (MESR), and the EU-program FEDER (Project NanoBio2, Nano'Mat Platform)
- Poloxamer 188;
- brain tumor
Etoposide (VP-16) is a hydrophobic anticancer agent inhibiting Topoisomerase II, commonly used in pediatric brain chemotherapeutic schemes as mildly toxic. Unfortunately, despite its appropriate solubilization in vehicle solvents, its poor bioavailability and limited passage of the blood–brain barrier concur to disappointing results requiring the development of new delivery system forms. In this study, etoposide formulated as a parenteral injectable solution (Teva®) was loaded into all-biocompatible poly(lactide-co-glycolide) (PLGA) or PLGA/P188-blended nanoparticles (size 110–130 nm) using a fully biocompatible nanoprecipitation technique. The presence of coprecipitated P188 on encapsulation efficacies and in vitro drug release was investigated. Drug encapsulation was determined using HPLC. Inflammatory response was checked by FACS analysis on human monocytes. Cytotoxic activity of the various simple (Teva®) or double (Teva®-loaded NPs) formulations was studied on the murine C6 and F98 cell lines. Obtained results suggest that, although noninflammatory neither nontoxic by themselves, the use of PLGA and PLGA/P188 nanoencapsulations over pre-existing etoposide formulation could induce a greatly improved cytotoxic activity. This approach demonstrated a promising perspective for parenteral delivery of VP16 and potential development of a therapeutic entity. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2013.